메뉴 건너뛰기




Volumn 11, Issue 11, 2011, Pages 1653-1665

Role of everolimus in pancreatic neuroendocrine tumors

Author keywords

Everolimus; mTOR inhibitor; Neuroendocrine tumors; Pancreas; RAD001; Sunitinib

Indexed keywords

CAPECITABINE; CYTOCHROME P450 3A4 INHIBITOR; ENZYME INHIBITOR; EVEROLIMUS; GLYCOPROTEIN P INHIBITOR; OCTREOTIDE; PLACEBO; SOMATOSTATIN DERIVATIVE; SUNITINIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG; YTTRIUM 90; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; RAPAMYCIN;

EID: 84858733911     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.145     Document Type: Article
Times cited : (8)

References (70)
  • 1
    • 46449110634 scopus 로고    scopus 로고
    • One hundred years after ‘carcinoid’: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States
    • Yao JC, Hassan M, Phan A et al. One hundred years after ‘carcinoid’: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 26(18), 3063-3072 (2008).
    • (2008) J. Clin. Oncol , vol.26 , Issue.18 , pp. 3063-3072
    • Yao, J.C.1    Hassan, M.2    Phan, A.3
  • 2
    • 55849088735 scopus 로고    scopus 로고
    • Neuroendocrine tumor epidemiology: Contrasting Norway and North America
    • Hauso O, Gustafsson BI, Kidd M et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 113(10), 2655-2664 (2008).
    • (2008) Cancer , vol.113 , Issue.10 , pp. 2655-2664
    • Hauso, O.1    Gustafsson, B.I.2    Kidd, M.3
  • 3
    • 55249090388 scopus 로고    scopus 로고
    • Gastrointestinal neuroendocrine tumors: Pancreatic endocrine tumors
    • Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 135(5), 1469-1492 (2008).
    • (2008) Gastroenterology , vol.135 , Issue.5 , pp. 1469-1492
    • Metz, D.C.1    Jensen, R.T.2
  • 4
    • 33947284588 scopus 로고    scopus 로고
    • Tumour biology and histopathology of neuroendocrine tumours
    • Klöppel G. Tumour biology and histopathology of neuroendocrine tumours. Best Pract. Res. Clin. Endocrinol. Metab. 21(1), 15-31 (2007).
    • (2007) Best Pract. Res. Clin. Endocrinol. Metab , vol.21 , Issue.1 , pp. 15-31
    • Klöppel, G.1
  • 5
    • 79959246002 scopus 로고    scopus 로고
    • Metastatic and locally advanced pancreatic endocrine carcinomas: Analysis of factors associated with disease progression
    • Panzuto F, Boninsegna L, Fazio N et al. Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J. Clin. Oncol. 29(17), 2372-2377 (2011).
    • (2011) J. Clin. Oncol , vol.29 , Issue.17 , pp. 2372-2377
    • Panzuto, F.1    Boninsegna, L.2    Fazio, N.3
  • 6
    • 33749032826 scopus 로고    scopus 로고
    • TNM staging of foregut (Neuro)endocrine tumors: A consensus proposal including a grading system
    • Rindi G, Klöppel G, Alhman H et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 449(4), 395-401 (2006).
    • (2006) Virchows Arch , vol.449 , Issue.4 , pp. 395-401
    • Rindi, G.1    Klöppel, G.2    Alhman, H.3
  • 7
    • 0030963446 scopus 로고    scopus 로고
    • Positional cloning of the gene for multiple endocrine neoplasiatype 1
    • Chandrasekharappa SC, Guru SC, Manickam P et al. Positional cloning of the gene for multiple endocrine neoplasiatype 1. Science 276(5311), 404-407 (1997).
    • (1997) Science , vol.276 , Issue.5311 , pp. 404-407
    • Chandrasekharappa, S.C.1    Guru, S.C.2    Manickam, P.3
  • 9
    • 79952279828 scopus 로고    scopus 로고
    • DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors
    • Jiao Y, Shi C, Edil BH et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331(6021), 1199-1203 (2011).
    • (2011) Science , vol.331 , Issue.6021 , pp. 1199-1203
    • Jiao, Y.1    Shi, C.2    Edil, B.H.3
  • 10
    • 0033534510 scopus 로고    scopus 로고
    • Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription
    • Agarwal SK, Guru SC, Heppner C et al. Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 96(1), 143-152 (1999).
    • (1999) Cell , vol.96 , Issue.1 , pp. 143-152
    • Agarwal, S.K.1    Guru, S.C.2    Heppner, C.3
  • 11
    • 0030748590 scopus 로고    scopus 로고
    • Novel pancreatic endocrine tumor suppressor gene locus on chromosome 3p with clinical prognostic implications
    • Chung DC, Smith AP, Louis DN, Graeme- Cook F, Warshaw AL, Arnold A. A novel pancreatic endocrine tumor suppressor gene locus on chromosome 3p with clinical prognostic implications. J. Clin. Invest. 100(2), 404-410 (1997).
    • (1997) J. Clin. Invest , vol.100 , Issue.2 , pp. 404-410
    • Chung, D.C.1    Smith, A.P.2    Louis, D.N.3    Graeme-Cook, F.4    Warshaw, A.L.5    Arnold, A.A.6
  • 13
    • 0031867308 scopus 로고    scopus 로고
    • Isolated liver metastases from neuroendocrine tumors: Does resection prolong survival
    • Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J. Am. Coll. Surg. 187(1), 88-92 (1998).
    • (1998) J. Am. Coll. Surg , vol.187 , Issue.1 , pp. 88-92
    • Chen, H.1    Hardacre, J.M.2    Uzar, A.3    Cameron, J.L.4    Choti, M.A.5
  • 15
    • 20944445859 scopus 로고    scopus 로고
    • Neuroendocrine hepatic metastases: Does aggressive management improve survival
    • Touzios JG, Kiely JM, Pitt SC et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann. Surg. 241(5), 776-783 (2005).
    • (2005) Ann. Surg , vol.241 , Issue.5 , pp. 776-783
    • Touzios, J.G.1    Kiely, J.M.2    Pitt, S.C.3
  • 16
    • 35348931680 scopus 로고    scopus 로고
    • Hepatic resection for metastatic gastrointestinal and pancreatic neuroendocrine tumours: Outcome and prognostic predictors
    • Gomez D, Malik HZ, Al-Mukthar A et al. Hepatic resection for metastatic gastrointestinal and pancreatic neuroendocrine tumours: outcome and prognostic predictors. HPB (Oxford) 9(5), 345-351 (2007).
    • (2007) HPB (Oxford) , vol.9 , Issue.5 , pp. 345-351
    • Gomez, D.1    Malik, H.Z.2    Al-Mukthar, A.3
  • 17
    • 26444475764 scopus 로고    scopus 로고
    • Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: Variables affecting response rates and survival
    • Gupta S, Johnson MM, Murthy R et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104(8), 1590-1602 (2005).
    • (2005) Cancer , vol.104 , Issue.8 , pp. 1590-1602
    • Gupta, S.1    Johnson, M.M.2    Murthy, R.3
  • 19
    • 44949120870 scopus 로고    scopus 로고
    • Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: Early results in 148 patients
    • Kennedy AS, Dezarn WA, McNeillie P et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am. J. Clin. Oncol. 31(3), 271-279 (2008).
    • (2008) Am. J. Clin. Oncol , vol.31 , Issue.3 , pp. 271-279
    • Kennedy, A.S.1    Dezarn, W.A.2    McNeillie, P.3
  • 20
    • 44449085489 scopus 로고    scopus 로고
    • Liu DM et al. 90Y radioembolization for metastatic neuroendocrine liver tumors: Preliminary results from a multi-institutional experience
    • Rhee TK, Lewandowski RJ, Liu DM et al. 90Y radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann. Surg. 247(6), 1029-1035 (2008).
    • (2008) Ann. Surg , vol.247 , Issue.6 , pp. 1029-1035
    • Rhee, T.K.1    Lewandowski, R.J.2
  • 21
    • 72949085528 scopus 로고    scopus 로고
    • Review article: Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours
    • Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment. Pharmacol. Ther. 31(2), 169-188 (2010).
    • (2010) Aliment. Pharmacol. Ther , vol.31 , Issue.2 , pp. 169-188
    • Modlin, I.M.1    Pavel, M.2    Kidd, M.3    Gustafsson, B.I.4
  • 22
    • 70350442637 scopus 로고    scopus 로고
    • Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group
    • Rinke A, Müller HH, Schade-Brittinger C et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J. Clin. Oncol. 27(28), 4656-4663 (2009).
    • (2009) J. Clin. Oncol , vol.27 , Issue.28 , pp. 4656-4663
    • Rinke, A.1    Müller, H.H.2    Schade-Brittinger, C.3
  • 23
    • 0026530547 scopus 로고
    • Streptozocindoxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma
    • Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocindoxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N. Engl. J. Med. 326(8), 519-523 (1992).
    • (1992) N. Engl. J. Med , vol.326 , Issue.8 , pp. 519-523
    • Moertel, C.G.1    Lefkopoulo, M.2    Lipsitz, S.3    Hahn, R.G.4    Klaassen, D.5
  • 24
    • 14644413806 scopus 로고    scopus 로고
    • Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locallyadvanced and metastatic pancreatic endocrine carcinomas
    • Kouvaraki MA, Ajani JA, Hoff P et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locallyadvanced and metastatic pancreatic endocrine carcinomas. J. Clin. Oncol. 22(23), 4762-4771 (2004).
    • (2004) J. Clin. Oncol , vol.22 , Issue.23 , pp. 4762-4771
    • Kouvaraki, M.A.1    Ajani, J.A.2    Hoff, P.3
  • 25
    • 0033567934 scopus 로고    scopus 로고
    • Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma
    • Cheng PN, Saltz LB. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 86(6), 944-948 (1999).
    • (1999) Cancer , vol.86 , Issue.6 , pp. 944-948
    • Cheng, P.N.1    Saltz, L.B.2
  • 26
    • 77950367451 scopus 로고    scopus 로고
    • Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours
    • Turner NC, Strauss SJ, Sarker D et al. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br. J. Cancer 102(7), 1106-1112 (2010).
    • (2010) Br. J. Cancer , vol.102 , Issue.7 , pp. 1106-1112
    • Turner, N.C.1    Strauss, S.J.2    Sarker, D.3
  • 27
    • 34249818466 scopus 로고    scopus 로고
    • Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors
    • Ekeblad S, Sundin A, Janson ET et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin. Cancer Res. 13(10), 2986-2991 (2007).
    • (2007) Clin. Cancer Res , vol.13 , Issue.10 , pp. 2986-2991
    • Ekeblad, S.1    Sundin, A.2    Janson, E.T.3
  • 28
    • 78650993549 scopus 로고    scopus 로고
    • First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas
    • Strosberg JR, Fine RL, Choi J et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117(2), 268-275 (2011).
    • (2011) Cancer , vol.117 , Issue.2 , pp. 268-275
    • Strosberg, J.R.1    Fine, R.L.2    Choi, J.3
  • 29
    • 58849093671 scopus 로고    scopus 로고
    • O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors
    • Kulke MH, Hornick JL, Frauenhoffer C et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin. Cancer Res. 15(1), 338-345 (2009).
    • (2009) Clin. Cancer Res , vol.15 , Issue.1 , pp. 338-345
    • Kulke, M.H.1    Hornick, J.L.2    Frauenhoffer, C.3
  • 30
    • 77951940409 scopus 로고    scopus 로고
    • Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs), a Phase II study
    • Cwikla JB, Sankowski A, Seklecka N et al. Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs), a Phase II study. Ann. Oncol. 21(4), 787-794 (2010).
    • (2010) Ann. Oncol , vol.21 , Issue.4 , pp. 787-794
    • Cwikla, J.B.1    Sankowski, A.2    Seklecka, N.3
  • 31
    • 79959208861 scopus 로고    scopus 로고
    • Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers
    • Imhof A, Brunner P, Marincek N et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J. Clin. Oncol. 29(17), 2416-2423 (2011).
    • (2011) J. Clin. Oncol , vol.29 , Issue.17 , pp. 2416-2423
    • Imhof, A.1    Brunner, P.2    Marincek, N.3
  • 32
    • 4344624707 scopus 로고    scopus 로고
    • Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3] octreotate
    • Teunissen JJ, Kwekkeboom DJ, Krenning EP. Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3] octreotate. J. Clin. Oncol. 22(13), 2724-2729 (2004).
    • (2004) J. Clin. Oncol , vol.22 , Issue.13 , pp. 2724-2729
    • Teunissen, J.J.1    Kwekkeboom, D.J.2    Krenning, E.P.3
  • 33
    • 74949122343 scopus 로고    scopus 로고
    • Pancreatic endocrine tumors: Expression profiling evidences a role for AKT-mTOR pathway
    • Missiaglia E, Dalai I, Barbi S et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J. Clin. Oncol. 28(2), 245-255 (2010).
    • (2010) J. Clin. Oncol , vol.28 , Issue.2 , pp. 245-255
    • Missiaglia, E.1    Dalai, I.2    Barbi, S.3
  • 34
    • 60749086869 scopus 로고    scopus 로고
    • Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: Novel chemotherapeutic targets in pancreatic endocrine tumors
    • Bergmann F, Breinig M, Höpfner M et al. Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors? Am. J. Gastroenterol. 104(1), 171-181 (2009).
    • (2009) Am. J. Gastroenterol , vol.104 , Issue.1 , pp. 171-181
    • Bergmann, F.1    Breinig, M.2    Höpfner, M.3
  • 35
    • 0031906775 scopus 로고    scopus 로고
    • Expression of vascular endothelial growth factor in digestive neuroendocrine tumours
    • Terris B, Scoazec JY, Rubbia L et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 32(2), 133-138 (1998).
    • (1998) Histopathology , vol.32 , Issue.2 , pp. 133-138
    • Terris, B.1    Scoazec, J.Y.2    Rubbia, L.3
  • 36
    • 79851500081 scopus 로고    scopus 로고
    • Everolimus for advanced pancreatic neuroendocrine tumors
    • Yao JC, Shah MH, Ito T, Bohas CL et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364(6), 514-523 (2011).
    • (2011) N. Engl. J. Med , vol.364 , Issue.6 , pp. 514-523
    • Yao, J.C.1    Shah, M.H.2    Ito, T.3    Bohas, C.L.4
  • 37
    • 79851482955 scopus 로고    scopus 로고
    • Sunitinib malate for the treatment of pancreatic neuroendocrine tumors
    • Raymond E, Dahan L, Raoul JL et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364(6), 501-513 (2011).
    • (2011) N. Engl. J. Med , vol.364 , Issue.6 , pp. 501-513
    • Raymond, E.1    Dahan, L.2    Raoul, J.L.3
  • 38
    • 0016713286 scopus 로고
    • Rapamycin (AY-22,989), a new antifungal antibiotic. Fermentation, isolation and characterization
    • Sehgal SN, Baker H, Vézina C. Rapamycin (AY-22,989), a new antifungal antibiotic. Fermentation, isolation and characterization. J. Antibiot. (Tokyo) 28(10), 727-732 (1975).
    • (1975) J. Antibiot. (Tokyo) , vol.28 , Issue.10 , pp. 727-732
    • Sehgal, S.N.1    Baker, H.2    Vézina, C.3
  • 39
    • 79952361568 scopus 로고    scopus 로고
    • Everolimus-based, calcineurin-inhibitorfree regimen in recipients of de-novo kidney transplants: An open-label, randomised, controlled trial
    • Budde K, Becker T, Arns W et al. Everolimus-based, calcineurin-inhibitorfree regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 377(9768), 837-847 (2011).
    • (2011) Lancet , vol.377 , Issue.9768 , pp. 837-847
    • Budde, K.1    Becker, T.2    Arns, W.3
  • 40
    • 0019870366 scopus 로고
    • Suffness M. New antitumor substances of natural origin. Cancer Treat
    • Douros J, Suffness M. New antitumor substances of natural origin. Cancer Treat. Rev. 8(1), 63-87 (1981).
    • (1981) Rev , vol.8 , Issue.1 , pp. 63-87
    • Douros, J.1
  • 41
    • 79954592882 scopus 로고    scopus 로고
    • MTOR signaling, function, novel inhibitors, and therapeutic targets
    • Watanabe R, Wei L, Huang J. mTOR signaling, function, novel inhibitors, and therapeutic targets. J. Nucl. Med. 52(4), 497-500 (2011).
    • (2011) J. Nucl. Med , vol.52 , Issue.4 , pp. 497-500
    • Watanabe, R.1    Wei, L.2    Huang, J.3
  • 42
    • 0034662634 scopus 로고    scopus 로고
    • Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells
    • von Wichert G, Jehle PM, Hoeflich A et al. Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res. 60(16), 4573-4581 (2000).
    • (2000) Cancer Res , vol.60 , Issue.16 , pp. 4573-4581
    • Von Wichert, G.1    Jehle, P.M.2    Hoeflich, A.3
  • 44
    • 0028342578 scopus 로고
    • Ampullary carcinoid and neurofibromatosis: Case report and review of the literature. Neth
    • van Basten JP, van Hoek B, de Bruïne A, Arends JW, Stockbrügger RW. Ampullary carcinoid and neurofibromatosis: case report and review of the literature. Neth. J. Med. 44(6), 202-206 (1994).
    • (1994) J. Med , vol.44 , Issue.6 , pp. 202-206
    • Van Basten, J.P.1    Van Hoek, B.2    De Bruïne, A.3    Arends, J.W.4    Stockbrügger, R.W.5
  • 45
    • 63449098382 scopus 로고    scopus 로고
    • MTOR inhibitor RAD001 (Everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor
    • Lane HA, Wood JM, McSheehy PM et al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin. Cancer Res. 15(5), 1612-1622 (2009).
    • (2009) Clin. Cancer Res , vol.15 , Issue.5 , pp. 1612-1622
    • Lane, H.A.1    Wood, J.M.2    McSheehy, P.M.3
  • 46
    • 9144233506 scopus 로고    scopus 로고
    • Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells
    • Boulay A, Zumstein-Mecker S, Stephan C et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res. 64(1), 252-261 (2004).
    • (2004) Cancer Res , vol.64 , Issue.1 , pp. 252-261
    • Boulay, A.1    Zumstein-Mecker, S.2    Stephan, C.3
  • 47
    • 45149094232 scopus 로고    scopus 로고
    • Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data
    • Tanaka C, O’Reilly T, Kovarik JM et al. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J. Clin. Oncol. 26(10), 1596-1602 (2008).
    • (2008) J. Clin. Oncol , vol.26 , Issue.10 , pp. 1596-1602
    • Tanaka, C.1    O’Reilly, T.2    Kovarik, J.M.3
  • 48
    • 43249131245 scopus 로고    scopus 로고
    • Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A Phase I tumor pharmacodynamic study in patients with advanced solid tumors
    • Tabernero J, Rojo F, Calvo E et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a Phase I tumor pharmacodynamic study in patients with advanced solid tumors. J. Clin. Oncol. 26(10), 1603-1610 (2008).
    • (2008) J. Clin. Oncol , vol.26 , Issue.10 , pp. 1603-1610
    • Tabernero, J.1    Rojo, F.2    Calvo, E.3
  • 49
    • 33947538050 scopus 로고    scopus 로고
    • Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
    • Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26(13), 1932-1940 (2007).
    • (2007) Oncogene , vol.26 , Issue.13 , pp. 1932-1940
    • Wan, X.1    Harkavy, B.2    Shen, N.3    Grohar, P.4    Helman, L.J.5
  • 50
    • 32944457518 scopus 로고    scopus 로고
    • She QB et al. MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
    • O’Reilly KE, Rojo F, She QB et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66(3), 1500-1508 (2006).
    • (2006) Cancer Res , vol.66 , Issue.3 , pp. 1500-1508
    • O’Reilly, K.E.1    Rojo, F.2
  • 51
    • 43249086546 scopus 로고    scopus 로고
    • Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors
    • O’Donnell A, Faivre S, Burris HA 3rd et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J. Clin. Oncol. 26(10), 1588-1595 (2008).
    • (2008) J. Clin. Oncol , vol.26 , Issue.10 , pp. 1588-1595
    • O’Donnell, A.1    Faivre, S.2    Burris, H.A.3
  • 52
    • 0035215119 scopus 로고    scopus 로고
    • Influence of hepatic impairment on everolimus pharmacokinetics: Implications for dose adjustment. Clin. Pharmacol
    • Kovarik JM, Sabia HD, Figueiredo J et al. Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. Clin. Pharmacol. Ther. 70(5), 425-430 (2001).
    • (2001) Ther , vol.70 , Issue.5 , pp. 425-430
    • Kovarik, J.M.1    Sabia, H.D.2    Figueiredo, J.3
  • 54
    • 52049125970 scopus 로고    scopus 로고
    • Efficacy of RAD001 (Everolimus) and octreotide LAR in advanced low- to intermediategrade neuroendocrine tumors: Results of a Phase II study
    • Yao JC, Phan AT, Chang DZ et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediategrade neuroendocrine tumors: results of a Phase II study. J. Clin. Oncol. 26(26), 4311-4318 (2008).
    • (2008) J. Clin. Oncol , vol.26 , Issue.26 , pp. 4311-4318
    • Yao, J.C.1    Phan, A.T.2    Chang, D.Z.3
  • 55
    • 73949088959 scopus 로고    scopus 로고
    • Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: A Phase II trial
    • Yao JC, Lombard-Bohas C, Baudin E et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a Phase II trial. J. Clin. Oncol. 28(1), 69-76 (2010).
    • (2010) J. Clin. Oncol , vol.28 , Issue.1 , pp. 69-76
    • Yao, J.C.1    Lombard-Bohas, C.2    Baudin, E.3
  • 57
    • 85041087255 scopus 로고    scopus 로고
    • Everolimus in patients with advanced pancreatic neuroendocrine tumors (PNET), impact of somatostatin analog use on progression-free survival in the RADIANT-3 trial
    • Chicago, IL, USA, 4-8 June
    • Shah MH, Lombard-Bohas C, Ito T. Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET), impact of somatostatin analog use on progression-free survival in the RADIANT-3 trial. Presented at: 2010 ASCO Annual Meeting. Chicago, IL, USA, 4-8 June 2011.
    • (2011) Presented At: 2010 ASCO Annual Meeting
    • Shah, M.H.1    Lombard-Bohas, C.2    Ito, T.3
  • 58
    • 79957566962 scopus 로고    scopus 로고
    • Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma
    • Porta C, Osanto S, Ravaud A et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur. J. Cancer 47(9), 1287-1298 (2011).
    • (2011) Eur. J. Cancer , vol.47 , Issue.9 , pp. 1287-1298
    • Porta, C.1    Osanto, S.2    Ravaud, A.3
  • 59
    • 48649107474 scopus 로고    scopus 로고
    • Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled Phase III trial
    • Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet 372(9637), 449-456 (2008).
    • (2008) Lancet , vol.372 , Issue.9637 , pp. 449-456
    • Motzer, R.J.1    Escudier, B.2    Oudard, S.3
  • 60
    • 85041047650 scopus 로고    scopus 로고
    • Everolimus in patients with advanced pancreatic neuroendocrine tumors (PNET), updated results of a randomized, double-blind, placebocontrolled, multicenter, Phase III trial (RADIANT-3).
    • Chicago, IL, USA, 4-8 June
    • Strosberg JR, Lincy J, Winkler RE, Wolin EM, Lee H. Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET), updated results of a randomized, double-blind, placebocontrolled, multicenter, Phase III trial (RADIANT-3). Presented at: 2010 ASCO Annual Meeting. Chicago, IL, USA, 4-8 June 2011.
    • (2011) Presented At: 2010 ASCO Annual Meeting
    • Strosberg, J.R.1    Lincy, J.2    Winkler, R.E.3    Wolin, E.M.4    Lee, H.5
  • 61
    • 68849123146 scopus 로고    scopus 로고
    • Everolimus (RAD001), an mTOR inhibitor for the treatment of metastatic renal cell carcinoma
    • Oudard S, Medioni J, Aylllon J et al. Everolimus (RAD001), an mTOR inhibitor for the treatment of metastatic renal cell carcinoma. Expert Rev. Anticancer Ther. 9(6), 705-717 (2009).
    • (2009) Expert Rev. Anticancer Ther , vol.9 , Issue.6 , pp. 705-717
    • Oudard, S.1    Medioni, J.2    Aylllon, J.3
  • 62
    • 85041025665 scopus 로고    scopus 로고
    • Prescribing information for everolimus from the FDA www.accessdata.fda.gov/drugsatfda_docs/label/2011/022344s9s10lbl.pdf
  • 63
    • 85041065367 scopus 로고    scopus 로고
    • Approval of everolimus for advanced renal cell carcinoma after prior therapy with sunitinib or sorafenib by the FDA www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022334s000_SumR.pdf
  • 64
    • 85041047115 scopus 로고    scopus 로고
    • Approval of everolimus for advanced renal cell carcinoma by the EMA www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/001038/WC500022815.pdf
  • 65
    • 85041036394 scopus 로고    scopus 로고
    • Approval of everolimus in advanced pancreatic neuroendocrine tumors by the FDA www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/022334s009,s010ltr.pdf
  • 66
    • 85041085591 scopus 로고    scopus 로고
    • Approval of sunitinib in advanced pancreatic neuroendocrine tumors by the FDA www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm256237.htm
  • 67
    • 85041057136 scopus 로고    scopus 로고
    • ClinicalTrials.gov. Phase I/II trial of everolimus in combination with temozolomide in advanced PNET http://clinicaltrials.gov/ct2/show/NCT005 76680?cond=pancreas&intr=everolimus& rank=13
  • 68
    • 85041083584 scopus 로고    scopus 로고
    • Phase I trial of everolimus combined with sorafenib in advanced neuroendocrine tumor
    • ClinicalTrials.gov. Phase I trial of everolimus combined with sorafenib in advanced neuroendocrine tumor http://clinicaltrials.gov/ct2/show/NCT00942682?cond=pancreas&intr=everolimus& rank=17
  • 69
    • 85041081463 scopus 로고    scopus 로고
    • Phase I trial of everolimus combined with pasireotide in advanced neuroendocrine tumor
    • ClinicalTrials.gov. Phase I trial of everolimus combined with pasireotide in advanced neuroendocrine tumor http://clinicaltrials.gov/ct2/show/NCT00 804336?cond=pancreas&intr=everolimus &rank=19
  • 70
    • 85041064976 scopus 로고    scopus 로고
    • Phase II trial of everolimus combined with erlotinib in advanced neuroendocrine tumor
    • ClinicalTrials.gov. Phase II trial of everolimus combined with erlotinib in advanced neuroendocrine tumor http://clinicaltrials.gov/ct2/show/NCT00843531?cond=pancreas&intr=everolimus &rank=31


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.